Trial · NCT00716079
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
NCT00716079, Not applicable, Completed, The George Institute; results first posted 2013-10-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial. Trials, record NCT00716079. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00716079
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
- NCT number
- NCT00716079
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,839 participants, actual
- Lead sponsor
- The George Institute
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Interventions
- Blood pressure management policies
- First posted
- 2008-07-16
- Last updated
- 2013-12-13
- Results first posted
- 2013-10-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | 90 days | |
| Secondary | Death at 90 Days | 90 days |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | 90 days | In the intensive group 12 patients were alive at 90 days but missing data on mRS (required for primary outcome), and 9 patients in the guideline group | participants | NUMBER |
| SECONDARY | Death at 90 Days | 90 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | Intensive Blood-Pressure Lowering | 719 | participants | ||
| A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | Guideline-Recommended Blood-Pressure Lowering | 785 | participants | ||
| Death at 90 Days | Intensive Blood-Pressure Lowering | 166 | participants | ||
| Death at 90 Days | Guideline-Recommended Blood-Pressure Lowering | 170 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intensive Blood-Pressure Lowering | 1,403 | |
| Overall Study | STARTED | Guideline-Recommended Blood-Pressure Lowering | 1,436 | |
| Overall Study | COMPLETED | Intensive Blood-Pressure Lowering | 1,394 | |
| Overall Study | COMPLETED | Guideline-Recommended Blood-Pressure Lowering | 1,421 | |
| Overall Study | NOT COMPLETED | Intensive Blood-Pressure Lowering | 9 | |
| Overall Study | NOT COMPLETED | Guideline-Recommended Blood-Pressure Lowering | 15 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Direct effects of primary ICH event | General disorders | Intensive Blood-Pressure Lowering | 143 | 1,399 | |
| serious | Direct effects of primary ICH event | General disorders | Guideline-Recommended Blood-Pressure Lowering | 154 | 1,430 | |
| serious | ICH | Vascular disorders | Intensive Blood-Pressure Lowering | 5 | 1,399 | |
| serious | ICH | Vascular disorders | Guideline-Recommended Blood-Pressure Lowering | 7 | 1,430 | |
| serious | Ischaemic/undifferentiated stroke | Vascular disorders | Intensive Blood-Pressure Lowering | 9 | 1,399 | |
| serious | Ischaemic/undifferentiated stroke | Vascular disorders | Guideline-Recommended Blood-Pressure Lowering | 8 | 1,430 | |
| serious | Acute MI/coronary event/other | Cardiac disorders | Intensive Blood-Pressure Lowering | 5 | 1,399 | |
| serious | Acute MI/coronary event/other | Cardiac disorders | Guideline-Recommended Blood-Pressure Lowering | 6 | 1,430 | |
| serious | Other vascular disease | Vascular disorders | Intensive Blood-Pressure Lowering | 15 | 1,399 | |
| serious | Other vascular disease | Vascular disorders | Guideline-Recommended Blood-Pressure Lowering | 16 | 1,430 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intensive Blood-Pressure Lowering | ||
| Total, all-cause mortality | Guideline-Recommended Blood-Pressure Lowering | ||
| Total, other adverse events | Intensive Blood-Pressure Lowering | 0 | 0 |
| Total, other adverse events | Guideline-Recommended Blood-Pressure Lowering | 0 | 0 |
| Total, serious adverse events | Intensive Blood-Pressure Lowering | 324 | 1,399 |
| Total, serious adverse events | Guideline-Recommended Blood-Pressure Lowering | 329 | 1,430 |
Source ClinicalTrials.gov
Papers43
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | Trial comparisons |
| Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: Death at 90 Days | Trial comparisons |
| Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00716079
GET https://conductscience.org/api/trials/v1/NCT00716079/events?page=2